Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 41, 2011, Pages 17165-17170

  Chantratita, Narisara ^a   Rholl, Drew A ^b   Sim, Bernice ^c   Wuthiekanun, Vanaporn ^a   Limmathurotsakul, Direk ^a   Amornchai, Premjit ^a   Thanwisai, Aunchalee ^a   Chua, Hui Hoon ^c   Ooi, Wen Fong ^c   Holden, Matthew T G ^d   Day, Nicholas P ^a,e   Tan, Patrick ^c,f   Schweizer, Herbert P ^b   Peacock, Sharon J ^a,d,g  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; DOXYCYCLINE; PENICILLIN BINDING PROTEIN; PENICILLIN BINDING PROTEIN 3; SULFAMETHOXAZOLE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BLOOD CULTURE; BURKHOLDERIA PSEUDOMALLEI; CELL CULTURE; CLINICAL ARTICLE; DNA SEQUENCE; DRUG TREATMENT FAILURE; GENE AMPLIFICATION; GENE DELETION; GENE LOSS; GENE MUTATION; HUMAN; IN VIVO STUDY; MELIOIDOSIS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; ASIA, SOUTHEASTERN; BASE SEQUENCE; BURKHOLDERIA PSEUDOMALLEI; CEFTAZIDIME; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; GENE DELETION; GENES, BACTERIAL; HUMANS; MELIOIDOSIS; PENICILLIN-BINDING PROTEINS; TREATMENT FAILURE;

BACTERIA (MICROORGANISMS); BURKHOLDERIA PSEUDOMALLEI;

EID: 80054730813     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1111020108     Document Type: Article

References (30)

1. Woodford N, Livermore DM (2009) Infections caused by Gram-positive bacteria: A review of the global challenge. J Infect 59(Suppl 1):S4-S16.
2. Livermore DM (1987) Mechanisms of resistance to cephalosporin antibiotics. Drugs 34(Suppl 2):64-88.
3. Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: A clinical update. Clin Microbiol Rev 18:657-686.
4. Piddock LJ (2006) Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 19:382-402.
5. Chierakul W, et al. (2005) Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim- sulfamethoxazole for the treatment of severe melioidosis. Clin Infect Dis 41:1105-1113. (Pubitemid 41429472)
6. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ (2006) Melioidosis: Insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 4:272-282.
7. Wuthiekanun V, Peacock SJ (2006) Management of melioidosis. Expert Rev Anti Infect Ther 4:445-455. (Pubitemid 43905466)
8. Dance DA, Wuthiekanun V, Chaowagul W, White NJ (1989) The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother 24:295-309. (Pubitemid 19238292)
9. Jenney AW, Lum G, Fisher DA, Currie BJ (2001) Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int J Antimicrob Agents 17:109-113. (Pubitemid 32101565)
10. Ashdown LR (1979) An improved screening technique for isolation of Pseudomonas pseudomallei from clinical specimens. Pathology 11:293-297.
11. Wuthiekanun V, Anuntagool N, White NJ, Sirisinha S (2002) Short report: A rapid method for the differentiation of Burkholderia pseudomallei and Burkholderia thailandensis. Am J Trop Med Hyg 66:759-761. (Pubitemid 35001051)
12. Cockerill FR, III (2010) Performance Standards for Antimicrobial Susceptibility Testing, Twentieth Informational Supplement, M100-S20 (Clinical and Laboratory Standards Inst, Wayne, PA), Vol 30, No 1.
13. Godoy D, et al. (2003) Multilocus sequence typing and evolutionary relationships among the causative agents of melioidosis and glanders, Burkholderia pseudomallei and Burkholderia mallei. J Clin Microbiol 41:2068-2079. (Pubitemid 36576536)
14. Ambler RP, et al. (1991) A standard numbering scheme for the class A beta-lactamases. Biochem J 276:269-270.
15. Tribuddharat C, Moore RA, Baker P, Woods DE (2003) Burkholderia pseudomallei class a beta-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition. Antimicrob Agents Chemother 47:2082-2087. (Pubitemid 36753554)
16. Sam IC, See KH, Puthucheary SD (2009) Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei. J Clin Microbiol 47:1556-1558.
17. Ho PL, Cheung TK, Yam WC, Yuen KY (2002) Characterization of a laboratory-generated variant of BPS beta-lactamase from Burkholderia pseudomallei that hydrolyses ceftazidime. J Antimicrob Chemother 50:723-726. (Pubitemid 35331691)
18. Chen K, Sun GW, Chua KL, Gan YH (2005) Modified virulence of antibiotic-induced Burkholderia pseudomallei filaments. Antimicrob Agents Chemother 49:1002-1009. (Pubitemid 40327716)
19. Maharjan B, et al. (2005) Recurrent melioidosis in patients in northeast Thailand is frequently due to reinfection rather than relapse. J Clin Microbiol 43:6032-6034. (Pubitemid 43100656)
20. Sim BM, et al. (2010) Genomic acquisition of a capsular polysaccharide virulence cluster by non-pathogenic Burkholderia isolates. Genome Biol 11:R89.
21. Holden MT, et al. (2004) Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci USA 101:14240-14245. (Pubitemid 39305059)
22. Nakamura M, et al. (1983) On the process of cellular division in Escherichia coli: Nucleotide sequence of the gene for penicillin-binding protein 3. Mol Gen Genet 191: 1-9. (Pubitemid 13016118)
23. Spratt BG (1975) Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12. Proc Natl Acad Sci USA 72:2999-3003.
24. Spratt BG (1977) Temperature-sensitive cell division mutants of Escherichia coli with thermolabile penicillin-binding proteins. J Bacteriol 131:293-305.
25. Hayes MV, Orr DC (1983) Mode of action of ceftazidime: Affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother 12:119-126. (Pubitemid 13034142)
26. Häussler S, Rohde M, Steinmetz I (1999) Highly resistant Burkholderia pseudomallei small colony variants isolated in vitro and in experimental melioidosis. Med Microbiol Immunol (Berl) 188:91-97.
27. Proctor RA, et al. (2006) Small colony variants: A pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 4:295-305.
28. Häussler S, Tümmler B, Weissbrodt H, Rohde M, Steinmetz I (1999) Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis. Clin Infect Dis 29:621-625. (Pubitemid 29439964)
29. Trunck LA, et al. (2009) Molecular basis of rare aminoglycoside susceptibility and pathogenesis of Burkholderia pseudomallei clinical isolates from Thailand. PLoS Negl Trop Dis 3:e519.
30. Dance DA, Wuthiekanun V, Naigowit P, White NJ (1989) Identification of Pseudomonas pseudomallei in clinical practice: Use of simple screening tests and API 20NE. J Clin Pathol 42:645-648. (Pubitemid 19156943)